Stock Events

Stock Events

Medincell. 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16JunExpected
Q3 2025
Next
-0.49
-0.32
-0.15
0.02
Expected EPS
0.01970599072
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MEB.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, competing in the drug delivery and development space similar to MedinCell's focus on controlled-release drug delivery technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals, known for its RNA-targeted drug discovery and development, competes with MedinCell in the development of novel therapeutics.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics, focusing on RNA-based therapeutics, particularly for rare diseases, competes in the innovative drug development sector alongside MedinCell.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals, with its focus on creating new treatments for serious diseases, shares the innovative drug development market with MedinCell.
Biogen
BIIB
Mkt Cap26.03B
Biogen, a biotechnology company specializing in therapies for neurological diseases, competes with MedinCell in the biopharmaceutical innovation and development space.
AMGEN
AMGN
Mkt Cap187.56B
Amgen, a biopharmaceutical company, competes in developing novel therapeutics, similar to MedinCell's focus on innovative drug delivery systems.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, known for its innovative biopharmaceuticals, competes with MedinCell in the area of drug development and novel therapies.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, focusing on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, competes in the pharmaceuticals and biotechnology industry alongside MedinCell.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk, a global healthcare company with a leading position in diabetes care, competes with MedinCell in the broader pharmaceuticals market, particularly in innovative drug delivery solutions.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, a global pharmaceutical corporation, competes across various therapeutic areas, including those targeted by MedinCell, with its extensive research and development in novel pharmaceuticals.

About

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
Show more...
CEO
Mr. Christophe Douat
Employees
145
Country
France
ISIN
FR0004065605

Listings

STU
DE
MEB.STU
F
DE
MEB.F
MU
DE
MEB.MU
PA
FR
MEDCL.PA

0 Comments

Share your thoughts

FAQ

What is Medincell. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medincell. stocks are traded under the ticker MEB.MU.
When is the next Medincell. earnings date?▼
Medincell. is going to release the next earnings report on June 16, 2026.
What were Medincell. earnings last quarter?▼
MEB.MU earnings for the last quarter are -0.49 EUR per share, whereas the estimation was -0.26 EUR resulting in a -88.46% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Medincell. have?▼
As of April 12, 2026, the company has 145 employees.
In which sector is Medincell. located?▼
Medincell. operates in the Health & Wellness sector.
When did Medincell. complete a stock split?▼
Medincell. has not had any recent stock splits.
Where is Medincell. headquartered?▼
Medincell. is headquartered in Jacou, France.